Biogen Reaches $900 Million Final Settlement of Kickback Claims, Whistleblower Share Set at $250 Million
- September 30, 2022
Biogen Inc. will pay $900 million to resolve a False Claims Act (FCA) lawsuit alleging that the company caused the submission of false claims to Medicare and Medicaid for its drugs that were tainted by kickbacks, U.S. Attorney for the District of Massachusetts Rachel S. Rollins announced September 26.
ARTICLE TAGS
You must be logged in to access this content.